Meeting
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors.
Authors
Ben George
Froedtert & The Medical College of Wisconsin, Milwaukee, WI
Ben George , Donald A. Richards , William Jeffery Edenfield , Steven L Warner , Lars Mouritsen , Reyna Bishop , Stephen Patrick Anthony , David Bearss , Nicholas J. Vogelzang , Clifford Whatcott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03298984
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3611)
DOI
10.1200/JCO.2020.38.15_suppl.3611
Abstract #
3611
Poster Bd #
341
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).
First Author: Philippe L. Bedard
Poster
2013 ASCO Annual Meeting
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
First Author: Gregory Lawrence Beatty
Poster
2023 ASCO Annual Meeting
Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).
First Author: Gregory Michael Cote
Poster
2021 ASCO Annual Meeting
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
First Author: Angela Tatiana Alistar